Rhea-AI Summary
NexGel director Jerome B. Zeldis received a stock option grant on June 25, 2025 for 30,000 shares of common stock at an exercise price of $2.32 per share. The options were granted under the company's 2019 Long-Term Incentive Plan for board service through the 2026 Annual Meeting.
Key terms of the stock option grant:
- Vesting schedule: Equal monthly installments of 2,500 shares over 12 months starting July 31, 2025
- Expiration date: June 25, 2035
- Exercise price: $2.32 per share
- Accelerated vesting provision in case of Change in Control
This Form 4 filing indicates continued alignment of director compensation with shareholder interests through equity-based incentives. The 10-year exercise period and monthly vesting schedule are typical for director equity compensation plans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
How many NEXGEL (NXGLW) SEC filings are available on StockTitan?
StockTitan tracks 53 SEC filings for NEXGEL (NXGLW), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.
When was the most recent SEC filing for NEXGEL (NXGLW)?
The most recent SEC filing for NEXGEL (NXGLW) was filed on June 28, 2025.